Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy
{{output}}
Aim: 177Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neuroendocrine tumors (NETs) in 2018. Cl... ...
